Initial therapy with cisplatin plus VP-16 in small-cell lung cancer

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Cisplatin plus VP-16 has become a widely used salvage regimen for CAV (cyclophosphomide, doxorubicin [Adriamycin], and vincristine) failures. However, the major value of this two-drug combination will probably be as an integral part of the initial therapeutic strategy. Cisplatin plus VP-16 has been used as induction therapy in four separate published studies involving 238 patients. The response rates ranged from 71% to 94% and complete remission (CR) rates varied from 30% to 53%. Cisplatin plus VP-16 has also been alternated with CAV in several phase II studies with encouraging results. A South-eastern Cancer Study Group (SECSG) protocol in extensive disease is currently testing this hypothesis in a random prospective study. A recently completed SECSG protocol in limited small-cell lung cancer tested the concept of late intensification with two courses of cisplatin plus VP-16 following six courses of CAV, v six courses of CAV alone. Presently, there is a statistically significant survival advantage for cisplatin plus VP-16.

Original languageEnglish
Pages (from-to)5-9
Number of pages5
JournalSeminars in Oncology
Volume13
Issue number3 SUPPL. 3
StatePublished - 1986

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Cisplatin
Doxorubicin
Therapeutics
Vincristine
Drug Combinations
Neoplasms
Prospective Studies
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Initial therapy with cisplatin plus VP-16 in small-cell lung cancer. / Einhorn, Lawrence.

In: Seminars in Oncology, Vol. 13, No. 3 SUPPL. 3, 1986, p. 5-9.

Research output: Contribution to journalArticle

@article{e456b00d87b84067874d5b71835e243a,
title = "Initial therapy with cisplatin plus VP-16 in small-cell lung cancer",
abstract = "Cisplatin plus VP-16 has become a widely used salvage regimen for CAV (cyclophosphomide, doxorubicin [Adriamycin], and vincristine) failures. However, the major value of this two-drug combination will probably be as an integral part of the initial therapeutic strategy. Cisplatin plus VP-16 has been used as induction therapy in four separate published studies involving 238 patients. The response rates ranged from 71{\%} to 94{\%} and complete remission (CR) rates varied from 30{\%} to 53{\%}. Cisplatin plus VP-16 has also been alternated with CAV in several phase II studies with encouraging results. A South-eastern Cancer Study Group (SECSG) protocol in extensive disease is currently testing this hypothesis in a random prospective study. A recently completed SECSG protocol in limited small-cell lung cancer tested the concept of late intensification with two courses of cisplatin plus VP-16 following six courses of CAV, v six courses of CAV alone. Presently, there is a statistically significant survival advantage for cisplatin plus VP-16.",
author = "Lawrence Einhorn",
year = "1986",
language = "English",
volume = "13",
pages = "5--9",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 3",

}

TY - JOUR

T1 - Initial therapy with cisplatin plus VP-16 in small-cell lung cancer

AU - Einhorn, Lawrence

PY - 1986

Y1 - 1986

N2 - Cisplatin plus VP-16 has become a widely used salvage regimen for CAV (cyclophosphomide, doxorubicin [Adriamycin], and vincristine) failures. However, the major value of this two-drug combination will probably be as an integral part of the initial therapeutic strategy. Cisplatin plus VP-16 has been used as induction therapy in four separate published studies involving 238 patients. The response rates ranged from 71% to 94% and complete remission (CR) rates varied from 30% to 53%. Cisplatin plus VP-16 has also been alternated with CAV in several phase II studies with encouraging results. A South-eastern Cancer Study Group (SECSG) protocol in extensive disease is currently testing this hypothesis in a random prospective study. A recently completed SECSG protocol in limited small-cell lung cancer tested the concept of late intensification with two courses of cisplatin plus VP-16 following six courses of CAV, v six courses of CAV alone. Presently, there is a statistically significant survival advantage for cisplatin plus VP-16.

AB - Cisplatin plus VP-16 has become a widely used salvage regimen for CAV (cyclophosphomide, doxorubicin [Adriamycin], and vincristine) failures. However, the major value of this two-drug combination will probably be as an integral part of the initial therapeutic strategy. Cisplatin plus VP-16 has been used as induction therapy in four separate published studies involving 238 patients. The response rates ranged from 71% to 94% and complete remission (CR) rates varied from 30% to 53%. Cisplatin plus VP-16 has also been alternated with CAV in several phase II studies with encouraging results. A South-eastern Cancer Study Group (SECSG) protocol in extensive disease is currently testing this hypothesis in a random prospective study. A recently completed SECSG protocol in limited small-cell lung cancer tested the concept of late intensification with two courses of cisplatin plus VP-16 following six courses of CAV, v six courses of CAV alone. Presently, there is a statistically significant survival advantage for cisplatin plus VP-16.

UR - http://www.scopus.com/inward/record.url?scp=0022971415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022971415&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 5

EP - 9

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 3

ER -